JAZZ - Jazz Pharmaceuticals begins enrollment in phase 2 trial of Zepzelca in advanced tumors

Jazz Pharmaceuticals (NASDAQ:JAZZ) said the first patient was enrolled in a phase 2 trial evaluating Zepzelca (lurbinectedin) as a monotherapy in three groups: patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination deficient (HRD) tumors who have progressed on a platinum-containing regimen. The mid-stage study, dubbed EMERGE-201, will primarily assess patient's objective response rates.

For further details see:

Jazz Pharmaceuticals begins enrollment in phase 2 trial of Zepzelca in advanced tumors